WIRE)–BioMimetic Therapeutics, Inc. today announced it will
introduce Augmatrix™ Biocomposite Bone Graft, a new bone graft substitute
product line, to surgeons and distributors at its exhibit booth during the
American Academy of Orthopedic Surgeons (AAOS) meeting this week in San
This Augmatrix product line is comprised of
carbonate-apatite (calcium phosphate) and Type I collagen and is designed to be
combined with bone marrow aspirate (BMA). The products are available in
multiple forms to suit an array of bone grafting challenges, including fracture
repair and general bone void filling procedures. The product line has been FDA
cleared for use in orthopedic indications and is ready for sale in the United States.
Aggregate sales of bone graft substitutes in the U.S. are estimated to reach $1.7B
in 2012, according to Millennium Research.
“We believe the addition of the Augmatrix product line will
provide surgeons with a range of bone grafting solutions to procedures for
which our rhPDGF-BB based offerings will not initially be indicated,” said Dr.
Samuel Lynch, president and CEO of BioMimetic Therapeutics. “The Augmatrix bone
graft substitute platform presents a perfect complement to our existing
orthobiologic portfolio and will allow us to penetrate the large bone graft
substitutes market earlier than anticipated. We look forward to adding
offerings to the Augmatrix program with the goal of expanding the sales of
these products through our current distribution network, while establishing a
commercial presence with surgeons and hospitals.”
The Companys exhibit booth (#4753) is located in Hall D of
the Moscone North Convention Center
and booth hours are 9:00 a.m.-5:00 p.m. PST from February 8-February 9 and 9:00
a.m.-4:00 p.m. PST February 10. Company management will be available to answer
product development questions and will host investor meetings at the exhibit
booth. Please contact BioMimetics corporate communications department for
About BioMimetic Therapeutics
BioMimetic Therapeutics is a biotechnology company specializing in the
development and commercialization of clinically proven products to promote the
healing of musculoskeletal injuries and diseases, including therapies for
orthopedics, sports medicine and spine applications. All Augment® branded
products are based upon recombinant human platelet-derived growth factor
(rhPDGF-BB), which is an engineered form of PDGF, one of the body’s principal
agents to stimulate and direct healing and regeneration. Through the
commercialization of this patented technology, BioMimetic seeks to become the
leading company in the field of regenerative medicine by providing new
treatment options for the repair of bone, cartilage, tendons and ligaments.
BioMimetic received regulatory approval in 2009 and 2011 to
market Augment® Bone Graft in Canada
and in Australia
for hindfoot and ankle fusion indications. Augment is pending regulatory
decisions in the U.S.
and European Union for similar indications. The Company also markets a bone
graft substitute line of products for orthopedic indications called Augmatrix
Biocomposite Bone Graft.